MetaCap

Erasca (ERAS) vs Ionis Pharmaceuticals (IONS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Erasca (ERAS) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 366.1% versus a loss of 65.1%. Over five years, IONS leads with a -8.5% price change compared with -11.3% for ERAS. Erasca is the larger company by market cap ($4.78 billion vs $4.43 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ERAS+366.10%IONS-65.07%
+706%+302%-102%
Nov 21, 20251 yearNov 20, 2026
ERAS-24.51%IONS-16.91%
+184%+38%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ERAS versus IONS key metrics
MetricERASIONS
Share price$13.61$26.58
Market cap$4.78B$4.43B
1-day change-4.29%-2.35%
YTD return+265.86%-66.40%
1-year return+366.10%-65.07%
5-year return-11.28%-8.50%
EPS (TTM)$-0.97$-3.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$943.71M
Revenue growth (YoY)—+33.83%
Net income (latest FY)$-124.55M$-381.39M
Gross margin—98.31%
Operating margin—-40.45%
Net margin—-40.41%
52-week high$24.28$86.74
52-week low$2.81$26.53
Distance from 52-week high-43.95%-69.36%
Analyst consensusbuybuy
Avg. price target upside+77.15%+155.19%
Average volume5.27M3.91M
Shares outstanding350.96M166.55M
Employees1031,485
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ERAS has outperformed IONS by 431.2 percentage points over the past year.

About Erasca

ERAS stock →

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees

About Ionis Pharmaceuticals

IONS stock →

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).

Health Care · Biotechnology: Pharmaceutical Preparations · 1,485 employees

ERAS vs IONS FAQ

Which is bigger, Erasca or Ionis Pharmaceuticals?

Erasca (ERAS) is larger, with a market capitalization of $4.78B compared with $4.43B for Ionis Pharmaceuticals (IONS).

Which stock has performed better over the past year, ERAS or IONS?

ERAS returned +366.10% over the past 12 months, compared with -65.07% for IONS (price return, excluding dividends). Past performance does not predict future results.

Are Erasca and Ionis Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons